November 4, 2021 -- Precigen has released initial results from phase I studies of drugs included in its UltraCAR-T and AdenoVerse platforms.
During a virtual event, trial investigators reported on the clinical progress of three therapies included in the company's UltraCAR-T platform: PRGN-3005, PRGN-3006, and PRGN-3007. In addition, presentations were given relating to two therapies in its AdenoVerse immunotherapy platform: PRGN-2009 off-the-shelf (OTS) AdenoVerse Immunotherapy and PRGN-2012 OTS AdenoVerse Immunotherapy.
The following data was presented:
UltraCAR-T therapies are composed of genetically modified autologous T cells that simultaneously express an antigen-specific CAR, membrane-bound interleukin-15 (IL-15), and a kill switch.
Including the gene-encoding, membrane-bound IL-15 slows the aging of UltraCAR-T cells and leads to increased expansion of cells in vivo. The kill switch allows for rapid destruction of UltraCAR-T cells in the event of adverse events, which increases the safety profile of the therapy, the company said.
Precigen received clearance from the U.S. Food and Drug Administration last year for manufacturing UltraCAR-T therapies.